VE416 Emerging Drug Insight and Market Forecast - 2032

“VE416 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about VE416 for Food Allergy in the 7MM. A detailed picture of the VE416 for Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the VE416 for Food Allergy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VE416 market forecast, analysis for Food Allergy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Food Allergy.

Drug Summary

VE416 is an orally-administered investigational live biotherapeutic product (LBP) consisting of a defined bacterial consortium. It is produced from pure, clonal bacterial cell banks, which yield a drug product of uniform composition in powdered form and free of any pathogenic strains, bypassing the need to rely on fecal donor material with inconsistent composition. In preclinical research, VE416 induced protective immunoregulatory responses and reduced anaphylaxis and allergic symptoms in sensitized mice.

In July 2019, Vedanta announced the first patient was enrolled in the Phase I/II clinical study of VE416, which is being conducted by Wayne Shreffler, M.D., Ph.D., chief of pediatric allergy and immunology and director of the Food Allergy Center at Massachusetts General Hospital. The study will explore VE416 both as a monotherapy and in combination with an oral peanut immunotherapy over the course of several months. Topline data is expected in 2022.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VE416 description, mechanism of action, dosage and administration, research and development activities in Food Allergy.
• Elaborated details on VE416 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VE416 research and development activity in Food Allergy details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VE416.
• The report contains forecasted sales of VE416 for Food Allergy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Food Allergy.
• The report also features the SWOT analysis with analyst views for VE416 in Food Allergy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VE416 Analytical Perspective

In-depth VE416 Market Assessment

This report provides a detailed market assessment of VE416 in Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for VE416.

VE416 Clinical Assessment

The report provides the clinical trials information of VE416 for Food Allergy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Food Allergy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VE416 dominance.
• Other emerging products for Food Allergy are expected to give tough market competition to VE416 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VE416 in Food Allergy.
• Our in-depth analysis of the forecasted sales data of VE416 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VE416 in Food Allergy.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of VE416?
• What is the clinical trial status of the study related to VE416 in Food Allergy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VE416 development?
• What are the key designations that have been granted to VE416 for Food Allergy?
• What is the forecasted market scenario of VE416 for Food Allergy?
• What are the forecasted sales of VE416 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Food Allergy and how are they giving competition to VE416 for Food Allergy?
• Which are the late-stage emerging therapies under development for the treatment of Food Allergy?